Search Medical Condition
Please enter condition
Please choose location
 

Guri-si, Korea, Republic of Clinical Trials

A listing of Guri-si, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (589) clinical trials

Cohort of Peripheral T Cell Lymphoma

Prospective evaluation of frequencies of febrile neutropenia or infectious complications in a homogeneous population of patients with peripheral T cell lymphoma

Phase N/A

0.0 miles

Learn More »

Bexagliflozin Efficacy and Safety Trial (BEST)

Approximately 130 investigative sites globally are planned to participate in this study. An estimated 1650 subjects with inadequately controlled T2DM and an elevated risk of cardiovascular adverse events will be randomized to bexagliflozin tablets, 20 mg, or placebo in a ratio of 2:1 in addition to the background anti-diabetic medications. ...

Phase

0.0 miles

Learn More »

A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer

Background of Hypothesis A. JCOG (Japanese Clinical Oncology Group) 9501 Study : Addition of aorta lymph node dissection to D2 lymph node dissection does not increase survival rate. Wide range of operation is not always the best treatment. If invasion rate can be kept as minimal as possible while maintaining ...

Phase

0.0 miles

Learn More »

Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease

ID1201 is a fruit extract of Melia toosendan. ID1201 alleviates Alzheimer's disease-type pathologies and cognitive deficit through the various actions of its effective components such as -secretase activation followed to A reduction, RAGE inhibition, neuro-protection, and anti-inflammatory activities.

Phase

0.0 miles

Learn More »

Learning Curve CUSUM of LV Ejection Fraction by Visual Estimation in Novice Practitioners

Eight EM residents who have no experience of echocardiography prior to the study were recruited as analysis of the echocardiographic image file. They received echocardiography interpretation skill training which included one hour of lecture. Twenty echocardiography videos files were provided during training session, they were instructed how to estimate EF ...

Phase N/A

0.0 miles

Learn More »

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active CD.

Phase

0.0 miles

Learn More »

Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients

GV1001 0.56 mg, 1.12 mg or placebo is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times. Control group (placebo): 30 subjects Study group 1 (GV1001 0.56 mg): 30 subjects Study ...

Phase

0.0 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.

Phase

0.0 miles

Learn More »

A Randomized Multicenter Open-label Parallel-group 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

To demonstrate superiority of QVA149 (110/50 g) once daily compared to tiotropium 18 g once daily in terms of trough forced expiratory volume in 1 second (FEV1) (mean of 45 min and 15 min pre-dose) following 12 weeks of treatment in mild to moderate symptomatic COPD patients

Phase

0.0 miles

Learn More »

Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients

There is a screening period of up to 6 weeks, a treatment period of a minimum of 52 weeks and a maximum of approximately up to 3 years after last patient is randomized, and a post-treatment follow-up period of 4 weeks. A total of up to 900 patients will be ...

Phase

0.0 miles

Learn More »